Injury-Induced Microvesicle Particle Release in Human Skin Explant Tissue

Katherine E. Fahy
*Wright State University - Main Campus*, ahy.3@wright.edu

Langni Liu
*Wright State University - Main Campus*, liu.106@wright.edu

Christina E. Borchers
*Wright State University - Main Campus*, christina.borchers@wright.edu

Richard Simman
*Wright State University - Main Campus*, richard.simman@wright.edu

Ji C. Bihl
*Wright State University - Main Campus*, ji.bihl@wright.edu

See next page for additional authors

Follow this and additional works at: https://corescholar.libraries.wright.edu/ptox

Part of the Chemicals and Drugs Commons

Repository Citation

This Presentation is brought to you for free and open access by the Pharmacology and Toxicology at CORE Scholar. It has been accepted for inclusion in Pharmacology and Toxicology Faculty Publications by an authorized administrator of CORE Scholar. For more information, please contact library-corescholar@wright.edu.
Injury-Induced Microvesicle Particle Release in Human Skin Explant Tissue
Katherine Fahy, Langni Liu, Christine Rapp, Christina Borchers, Richard Simman, Ji Bihl, Jeffrey B. Travers
Pharmacology and Toxicology Department, Wright State University, Dayton Ohio

Abstract

Microvesicle particles (MVPs) are 100-1000 nm vesicles that bud from the cell membrane and transmit intercellular signals locally and systemically via their bioactive cargo (e.g., cytokines). We have previously shown that thermal burn injury or UV radiation result in the formation of Microvesicle Particle (MVP) in keratinocytes. Thermal burn and UV radiation can result in systemic effects, even though their injury is localized to the skin. We therefore propose that PMF-producer injuries, UVB irradiation or thermal burn injury, result in the formation of MVPs that can potentially transport cytokines through the blood stream and induce systemic effects. This study, in part, addresses that proposed mechanism by demonstrating increased MVP release after thermal burn injury in vivo and ex vivo. In vivo there was a significant increase in MVP concentration in mouse skin that received thermal burn injury compared to untreated skin. This demonstrates that there is an increase in MVP release after injury in living models. Human skin explants that received suction blisters to separate the epidermis from the dermis exhibited increased MVP release into the blister fluid in response to CPAF, UVB or thermal burn injury as compared to controls, suggesting epidermal MVPs are mobile and can exit the epidermis. Acid Sphingomyelinase (aSMase), an enzyme that breaks sphingomyelin into ceramide and phosphorylcholine, has been found to be involved in MVP release in other cell types. Utilizing an FDA approved aSMase inhibitor, Imipramine, we found that UVB, CPAF and thermal burn-mediated MVP release is completely dependent on aSMase in keratinocyte cell lines and human explant skin. These results suggest that PMF-producing skin injuries (thermal burn and UVB) can induce MVP release, and the release can be therapeutically inhibited by Imipramine.

Results: Punch Biopsy Method

Results: Blister Method

Conclusions

- There was a significant increase in MVP concentration in mouse skin after thermal burn injury.
- This demonstrates that there is an increase in MVP release after injury in living models.
- CPAF, UVB and thermal burn injury on human ex vivo skin does increase the amount of MVP release compared to untreated skin.
- When the roof of a blister is damaged with thermal burn injury there is increased MVP in the blister fluid compared to untreated blisters.
- This demonstrates that MVPs were derived from the epidermis and are traveling to the dermis.
- Thermal Burn, UVB and CPAF seem to involve different mechanisms in MVP release.
- For burn treatment this mechanism seems to involve NF-κB, ERK1/2, Jun-kinase, and p38.
- For UVB treatment this mechanism seems to involve Jun-kinase, p38, and Rho kinases.
- For CPAF treatment this mechanism seems to involve NF-κB, ERK1/2, Jun-kinase, p38, and Rho kinases.
- For all three treatments (CPAF, UVB, and thermal burn), the increase in MVP release seem to be completely dependent on aSMase.
- As these MVP carry bioactive substances that may be regulating systemic effects of UVB and thermal burn, aSMase inhibitors like Imipramine may be a potential therapeutic agent to prevent these effects.

Acknowledgments

PI: Dr. Travers, M.D., Ph.D.
Sycamore Medical Center for Donating the explant tissue
Studies were funded by NIH RO1 HL062996 and VA Basic Merit Grant BX000853